This course aims to cover the following objectives, which will be presented in five individual online modules:
Appreciate the benefits of routine evaluation of patient-rated outcome measures as it pertains to patient-centered, whole person health care, evidence-based practice, and driving treatment decisions
Define and describe fundamental concepts of clinical outcomes assessment included disablement models, clinician vs. patient-rated outcomes, generic vs. specific patient-rated outcome measures, and single vs. multi-item patient-rated outcome measures
Identify commonly used patient-rated outcome measures for use in athletic populations
Implement strategies to evaluate patient outcomes in clinical practice
Discuss the value of using outcomes data collection for professional advancement

Please note that following the five modules, you will be asked to answer 10 knowledge questions about the content presented in the modules. Additionally, be sure to view each module in its entirety. It is recommended to take notes as you will not be permitted to return to a module once you have proceeded forward.

** This EBP home study course will take approximately 1.75 hours to complete **

To receive 1.75 EBP CEUs for this home study course, you must receive at least a 70% on the knowledge assessment. Following the completion of the course and knowledge assessment, you will receive an email from the AT-PBRN with your EBP CEU certificate, if warranted.

If you have any questions at any point throughout the home study course, please contact the AT-PBRN using the following link: Contact the AT-PBRN

Although injury prevention is a domain for athletic trainers (ATs), implementation science is a burgeoning area and many ATs may not have had specific education on preventive training program (PTP) implementation. This course aims to describe the most recent evidence on the benefits PTPs have on athlete injury risk, injury rate and sport performance. Additionally, ATs may not have the time to run PTPs every single day in their clinical setting. Coaches, particularly at the high school level do not utilize PTPs.  ATs can train coaches to effectively implement PTPs with their athletes, however ATs may not have background on the most effective strategies to train coaches. This course will present a framework that ATs can use to begin the PTP implementation process within their own settings.

The specific objectives for this course include the development of the participant’s ability to:

1. Discuss the current state of evidence for preventive training programs (PTPs)
2. Describe the 7-steps for successful PTP design and development
3. Prepare strategies for PTP implementation in different sport-specific or setting-specific scenarios, including but not limited to, youth sport, girls’ basketball, and the military.

According to the education levels described by the PDC, this continuing education course is considered to be Essential Level, and is appropriate for all athletic trainers.

(1.0 EBP CEUs – FREE)

Lateral ankle sprains (LAS) are the most common injuries associated with physical activity and athletic participation. Up to 70% of individuals who sustain a single LAS will eventually develop chronic ankle instability (CAI), which has been associated with long-term consequences such as decreased health-related quality of life and decreased physical activity. To help mitigate consequences related to CAI, recent studies have investigated different approaches in managing patients who suffer a LAS, including the use of patient-reported outcome measures, clinician-reported outcome measures, and various treatment approaches. Although LAS present a major challenge for health care providers, particularly athletic trainers, little is known about the overall effectiveness of current treatment strategies for LAS. Thus, there is a pressing need to identify effective treatment strategies that will optimize patient outcomes and reduce re-injury risk.

While treatments should be individualized, balance training has been shown to be an effective strategy to improve postural control and reduce recurrent LAS risk, and should be a part of every LAS rehabilitation protocol. ATs should use a combination of patient-reported outcome measures and clinician-rated outcome measures to guide the treatment and management of LAS and to improve patient outcomes, reduce the risk of LAS re-injury, and prevent the onset of CAI.

The specific objectives for this course include the development of the participant’s ability to:

1. Discuss the progression of an acute lateral ankle sprain to chronic ankle instability
2. Describe the evidence regarding the treatment of lateral ankle sprain injuries
3. Identify patient-reported outcome measures and clinician-rated outcome measures appropriate for lateral ankle sprain rehabilitation

According to the education levels described by the PDC, this continuing education course is considered to be Advanced Level, and is appropriate for all athletic trainers.

(0.75 EBP CEUs – FREE)

PROGRAM CANCELLED – DUE TO COVID-19

Systematic Approaches to Osteopathic Manipulative Medicine

Oct. 1-3, 2020 Postponed to 2021 Dates TBD

Click MORE for program information and tuition pricing.

Evidence-Based Content: It is the policy of the ATSU to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

ATSU Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, CESC, presenters, faculty, authors) participating in an educational activity provided by the ATSU are required to disclose to the provider any relevant financial relationships with any commercial interest. ATSU must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Disclosure Statement: It is the policy of the ATSU Continuing Education Department to ensure balance, independence, objectivity and scientific rigor in all its educational programs.  Faculty disclosures will be made in the course syllabus and/or during faculty introductions.  The audience is advised that one or more presentations in this continuing education activity may contain references of unlabeled or unapproved uses of drugs or devices.

Resolution/Mechanism of Identified Conflict of Interest: Independent sources of review include the following: All disclosures will be reviewed by the program/course directors, CE Assistant Vice President, or CE Director for identification of conflicts of interest. Reviewers, working with the program directors will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

• Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director
• Limit content to evidence with no recommendations
• Introduction of a debate format with an unbiased moderator (point-counterpoint)
• Inclusion of moderated panel discussion
• Publication of a parallel or rebuttal article for an article that is felt to be biased
• Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
• Divestiture of the relationship by faculty-The reviewer should be a physician or other scientist with knowledge of the specialty area being reviewed and often times the Assistant Vice President of Continuing Education will perform this first review and can then appoint an independent reviewer.-The independent reviewer is not be involved in the planning of this CME Activity and cannot have a relationship with any corporate entity supporting the CME activity.-The reviewer should have a copy of this policy and a copy of the Standards for Commercial Support to fully grasp their responsibilities as the reviewer. Off-Label or Unapproved Use of Drugs or Devices

It is the policy of the ATSU to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by the presenters and planners of educational content in this program are their own and do not necessarily represent the viewpoint of the ATSU.

Consent to Use of Photographic Images: Registration and attendance at or participation in ATSU meetings and other activities constitutes an agreement by the registrant to ATSU’s use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside ATSU meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this ATSU course is prohibited without the written permission from individual authors and ATSU.

Special Assistance: ATSU complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the CE staff at the registration desk or call 660-626-2232 for assistance.

stance.</p

Description:
This course presents essential evidence-based tests and measures used for
examination of neurologic impairments, activity limitations, and
participation restrictions with application to case studies. The focus of the
course is practicing and applying these outcome measures organized
according to International Classification of Functioning, Disability and Health
(ICF) levels.

Objectives:
At completion of this course, the participant will be able to:
• Discuss the choice of outcome measures based on the ICF model,
psychometric properties, and recomendations from the StrokEDGE, TBI EDGE,
and Core Measures CPG of the Academy of Neurologic Physical Therapy
• Demonstrate tests and measures of impairment, activity limitations and
participation measures for individuals with stroke and traumatic brain injury
• Make recommendations for tests and measures for individuals with stroke
and brain injury

Course Instructors: 

Cecelia Glittenberg, PT, PhD; Virginia Little, PT, PhD; Tracy Ellison, PT, DPT

11-12.25 Contact hours earned at course completion

*Course limited to 24 participants

VIRTUAL PROGRAM DETAILS COMING SOON!

Dec. 3-4, 2020

Click MORE for program information and tuition pricing.

Evidence-Based Content: It is the policy of the ATSU to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

ATSU Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, CESC, presenters, faculty, authors) participating in an educational activity provided by the ATSU are required to disclose to the provider any relevant financial relationships with any commercial interest. ATSU must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Disclosure Statement: It is the policy of the ATSU Continuing Education Department to ensure balance, independence, objectivity and scientific rigor in all its educational programs.  Faculty disclosures will be made in the course syllabus and/or during faculty introductions.  The audience is advised that one or more presentations in this continuing education activity may contain references of unlabeled or unapproved uses of drugs or devices.

Resolution/Mechanism of Identified Conflict of Interest: Independent sources of review include the following: All disclosures will be reviewed by the program/course directors, CE Assistant Vice President, or CE Director for identification of conflicts of interest. Reviewers, working with the program directors will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

• Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director
• Limit content to evidence with no recommendations
• Introduction of a debate format with an unbiased moderator (point-counterpoint)
• Inclusion of moderated panel discussion
• Publication of a parallel or rebuttal article for an article that is felt to be biased
• Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
• Divestiture of the relationship by faculty-The reviewer should be a physician or other scientist with knowledge of the specialty area being reviewed and often times the Assistant Vice President of Continuing Education will perform this first review and can then appoint an independent reviewer.-The independent reviewer is not be involved in the planning of this CME Activity and cannot have a relationship with any corporate entity supporting the CME activity.-The reviewer should have a copy of this policy and a copy of the Standards for Commercial Support to fully grasp their responsibilities as the reviewer. Off-Label or Unapproved Use of Drugs or Devices

It is the policy of the ATSU to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by the presenters and planners of educational content in this program are their own and do not necessarily represent the viewpoint of the ATSU.

Consent to Use of Photographic Images: Registration and attendance at or participation in ATSU meetings and other activities constitutes an agreement by the registrant to ATSU’s use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside ATSU meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this ATSU course is prohibited without the written permission from individual authors and ATSU.

Special Assistance: ATSU complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the CE staff at the registration desk or call 660-626-2232 for assistance.

Primary Care Update

Jan. 24-31, 2021

Click MORE for program information and tuition pricing.

ROYAL CARIBBEAN – Freedom of the Seas
7-night | Southern Caribbean
Cruise Departure: San Juan, Puerto Rico
Ports: Philipsburg, St. Maarten | Basseterre, St. Kitts & Nevis | Oranjestad, Aruba | Kralendijk, Bonaire

SAVE THE DATE! 
Mark your calendars and plan to attend!

Evidence-Based Content: It is the policy of the ATSU to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

ATSU Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, CESC, presenters, faculty, authors) participating in an educational activity provided by the ATSU are required to disclose to the provider any relevant financial relationships with any commercial interest. ATSU must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Disclosure Statement: It is the policy of the ATSU Continuing Education Department to ensure balance, independence, objectivity and scientific rigor in all its educational programs.  Faculty disclosures will be made in the course syllabus and/or during faculty introductions.  The audience is advised that one or more presentations in this continuing education activity may contain references of unlabeled or unapproved uses of drugs or devices.

Resolution/Mechanism of Identified Conflict of Interest: Independent sources of review include the following: All disclosures will be reviewed by the program/course directors, CE Assistant Vice President, or CE Director for identification of conflicts of interest. Reviewers, working with the program directors will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

• Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director
• Limit content to evidence with no recommendations
• Introduction of a debate format with an unbiased moderator (point-counterpoint)
• Inclusion of moderated panel discussion
• Publication of a parallel or rebuttal article for an article that is felt to be biased
• Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
• Divestiture of the relationship by faculty-The reviewer should be a physician or other scientist with knowledge of the specialty area being reviewed and often times the Assistant Vice President of Continuing Education will perform this first review and can then appoint an independent reviewer.-The independent reviewer is not be involved in the planning of this CME Activity and cannot have a relationship with any corporate entity supporting the CME activity.-The reviewer should have a copy of this policy and a copy of the Standards for Commercial Support to fully grasp their responsibilities as the reviewer. Off-Label or Unapproved Use of Drugs or Devices

It is the policy of the ATSU to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by the presenters and planners of educational content in this program are their own and do not necessarily represent the viewpoint of the ATSU.

Consent to Use of Photographic Images: Registration and attendance at or participation in ATSU meetings and other activities constitutes an agreement by the registrant to ATSU’s use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside ATSU meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this ATSU course is prohibited without the written permission from individual authors and ATSU.

Special Assistance: ATSU complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the CE staff at the registration desk or call 660-626-2232 for assistance.

Primary Care Update

Mar. 4-6, 2021

Click MORE for program information and tuition pricing.

SAVE THE DATE! 
Mark your calendars and plan to attend!

Evidence-Based Content: It is the policy of the ATSU to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

ATSU Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, CESC, presenters, faculty, authors) participating in an educational activity provided by the ATSU are required to disclose to the provider any relevant financial relationships with any commercial interest. ATSU must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Disclosure Statement: It is the policy of the ATSU Continuing Education Department to ensure balance, independence, objectivity and scientific rigor in all its educational programs.  Faculty disclosures will be made in the course syllabus and/or during faculty introductions.  The audience is advised that one or more presentations in this continuing education activity may contain references of unlabeled or unapproved uses of drugs or devices.

Resolution/Mechanism of Identified Conflict of Interest: Independent sources of review include the following: All disclosures will be reviewed by the program/course directors, CE Assistant Vice President, or CE Director for identification of conflicts of interest. Reviewers, working with the program directors will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

• Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director
• Limit content to evidence with no recommendations
• Introduction of a debate format with an unbiased moderator (point-counterpoint)
• Inclusion of moderated panel discussion
• Publication of a parallel or rebuttal article for an article that is felt to be biased
• Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
• Divestiture of the relationship by faculty-The reviewer should be a physician or other scientist with knowledge of the specialty area being reviewed and often times the Assistant Vice President of Continuing Education will perform this first review and can then appoint an independent reviewer.-The independent reviewer is not be involved in the planning of this CME Activity and cannot have a relationship with any corporate entity supporting the CME activity.-The reviewer should have a copy of this policy and a copy of the Standards for Commercial Support to fully grasp their responsibilities as the reviewer. Off-Label or Unapproved Use of Drugs or Devices

It is the policy of the ATSU to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by the presenters and planners of educational content in this program are their own and do not necessarily represent the viewpoint of the ATSU.

Consent to Use of Photographic Images: Registration and attendance at or participation in ATSU meetings and other activities constitutes an agreement by the registrant to ATSU’s use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside ATSU meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this ATSU course is prohibited without the written permission from individual authors and ATSU.

Special Assistance: ATSU complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the CE staff at the registration desk or call 660-626-2232 for assistance.

Sponsored by the Orthopedic and Neurologic Physical Therapy Residency programs at A.T. Still University in conjunction with the Physical Therapy Department in the Arizona School of Health Sciences. The Orthopedic and Neurologic Physical Therapy Residency programs are accredited by the American Board of Physical Therapy Residency & Fellowship Education (ABPTRFE).

Course Instructor: Lori Bordenave, PT, DPT, PhD, Tawna Wilkinson, PT, DPT, PhD, and Tracy Ellison, PT, DPT

Course Times:

Friday 11/15: 12pm – 5pm

Saturday 11/16: 8am – 5pm

Sunday 11/17: 8am – 12pm

Course Description: This program is designed primarily for people interested in or involved with clinical education (clinical instructors [CIs], Site Coordinator of Clinical Education [SCCEs], Director of Clinical Education [DCEs]) and is recognized by APTA as a Clinical Instructor (CI) Education and Credentialing Program.

Course Objectives:
1. Preparing for physical therapy students during their clinical education experiences

2. Developing learning experiences

3. Supporting ongoing learning through questioning and effective feedback

4. Developing skills of performance evaluation

5. Identifying and managing students with exceptional situations

6. Identifying legal implications for clinical educators, including issues presented by ADA legislation

CEU: Participants are awarded 1.5 CEUs or 15 contact hours at the end of the course.

FIRM REGISTRATION DEADLINE: March 5, 2021

ATSU Physical Therapy Department is qualified to provide physical therapist continuing education courses and activities according to the Arizona State Board of Physical Therapy (Rule R4-24-402).

CEU courses and other post-professional programs offered at ATSU are not associated with the CAPTE accredited residential Doctor of Physical Therapy program

PROGRAM CANCELLED – DUE TO COVID-19

Diabetes Update

April 16-18, 2021

Click MORE for program information and tuition pricing.

Evidence-Based Content: It is the policy of the ATSU to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

ATSU Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, CESC, presenters, faculty, authors) participating in an educational activity provided by the ATSU are required to disclose to the provider any relevant financial relationships with any commercial interest. ATSU must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Disclosure Statement: It is the policy of the ATSU Continuing Education Department to ensure balance, independence, objectivity and scientific rigor in all its educational programs.  Faculty disclosures will be made in the course syllabus and/or during faculty introductions.  The audience is advised that one or more presentations in this continuing education activity may contain references of unlabeled or unapproved uses of drugs or devices.

Resolution/Mechanism of Identified Conflict of Interest: Independent sources of review include the following: All disclosures will be reviewed by the program/course directors, CE Assistant Vice President, or CE Director for identification of conflicts of interest. Reviewers, working with the program directors will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

• Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director
• Limit content to evidence with no recommendations
• Introduction of a debate format with an unbiased moderator (point-counterpoint)
• Inclusion of moderated panel discussion
• Publication of a parallel or rebuttal article for an article that is felt to be biased
• Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
• Divestiture of the relationship by faculty-The reviewer should be a physician or other scientist with knowledge of the specialty area being reviewed and often times the Assistant Vice President of Continuing Education will perform this first review and can then appoint an independent reviewer.-The independent reviewer is not be involved in the planning of this CME Activity and cannot have a relationship with any corporate entity supporting the CME activity.-The reviewer should have a copy of this policy and a copy of the Standards for Commercial Support to fully grasp their responsibilities as the reviewer. Off-Label or Unapproved Use of Drugs or Devices

It is the policy of the ATSU to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by the presenters and planners of educational content in this program are their own and do not necessarily represent the viewpoint of the ATSU.

Consent to Use of Photographic Images: Registration and attendance at or participation in ATSU meetings and other activities constitutes an agreement by the registrant to ATSU’s use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside ATSU meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this ATSU course is prohibited without the written permission from individual authors and ATSU.

Special Assistance: ATSU complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the CE staff at the registration desk or call 660-626-2232 for assistance.